About ImmunSYS
ImmunSYS is a company based in Delray Beach (United States) founded in 2018. ImmunSYS has raised $5.48 million across 2 funding rounds. ImmunSYS offers products and services including YourVaccx™ and ANTIGENerator™. ImmunSYS operates in a competitive market with competitors including Imvax, BriaCell Therapeutics, Radionetics, Hinova Pharmaceuticals and Convergent Therapeutics, among others.
- Headquarter Delray Beach, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immunsys, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.48 M (USD)
in 2 rounds
-
Latest Funding Round
$283.27 K (USD), Series A
Apr 20, 2020
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ImmunSYS
ImmunSYS offers a comprehensive portfolio of products and services, including YourVaccx™ and ANTIGENerator™.
Therapy empowering immune system to attack metastatic cancer cells.
Device that lyses tumor cells to release antigens for immunotherapy.
People of ImmunSYS
Unlock access to complete
Unlock access to complete
Advisor Team
6 people
Leadership Team
2 people
CSO Team
1 people
Finance and Accounting
1 people
Patient Team
1 people
Unlock access to complete
Funding Insights of ImmunSYS
ImmunSYS has successfully raised a total of $5.48M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $283.27 thousand completed in April 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by ImmunSYS
Investment portfolio details for ImmunSYS
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ImmunSYS
Detailed financials for ImmunSYS
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immunsys Comparisons
Peer comparison for ImmunSYS
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ImmunSYS
ImmunSYS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Imvax, BriaCell Therapeutics, Radionetics, Hinova Pharmaceuticals and Convergent Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Patient-specific cell vaccines for glioma treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of cancer
|
|
| Locked | Locked | Locked |
Peptide-targeted radiopharmaceuticals for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Develops small molecule based drug for multiple disease treatment
|
|
| Locked | Locked | Locked |
Cancer therapeutics are developed using dual-targeted radionuclide therapy.
|
|
| Locked | Locked | Locked |
Drugs are developed for intrinsically disordered protein targets.
|
Detailed competitors of ImmunSYS
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunsys
Complete news archive for ImmunSYS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImmunSYS
ImmunSYS was founded in 2018 and raised its 1st funding round 1 year after it was founded.
ImmunSYS is headquartered in Delray Beach, United States. It is registered at Delray Beach, Florida, United States.
ImmunSYS is a funded company, having raised a total of $5.48M across 2 funding rounds to date.
ImmunSYS was founded in 2018 in Delray Beach, United States, with operations centered in the biotechnology sector. Development efforts are directed toward immunotherapeutics drugs and devices targeting late-stage metastatic prostate cancer. The lead candidate, MyVaccx, is advanced as a clinical-stage immunotherapeutic agent. This involves integration of a proprietary antigen presentation medical device system and intra-tumoral injection of a depot drug formulation containing immunotherapeutics and an immunostimulant.
ImmunSYS's top competitors include Imvax, BriaCell Therapeutics and Radionetics.
ImmunSYS offers YourVaccx™ and ANTIGENerator™.